CADTH is pleased to announce that, after a hiatus in 2022, we are once again accepting nominations for the CADTH Recognition Awards. These 2 awards recognize achievement and excellence in Canada’s health technology assessment (HTA) community.
The Dr. Jill M. Sanders Award of Excellence in Health…
January 26, 2023
November 14 to 20
In celebration of Digital Health Week, CADTH is proud to share some of the evidence we have delivered to inform decisions about digital health technologies in categories that span artificial intelligence, smartphone apps, virtual care, and more.
Visit Our Digital Health Evidence…
November 14, 2022
Today, CADTH, on behalf of the Real-World Evidence Steering Committee, launched a public consultation to solicit feedback on a pan-Canadian guidance document that will inform the use of real-world evidence (RWE) that may be submitted for consideration in regulatory and reimbursement decision-making…
November 9, 2022
Today CADTH is proud to mark World Evidence-Based Healthcare (EBHC) Day, a global initiative to highlight the critical role of evidence in improving health outcomes, enhancing clinical care, and informing policy .
The 2022 World EBHC Day campaign focuses on partnerships within the global evidence…
October 20, 2022
Six health technology assessment (HTA) bodies from 3 continents will join forces to collaborate on a range of topics to benefit people accessing health care around the world.
The signatories to the arrangement, who will continue to remain independent of one another, are:
National Institute for…
September 6, 2022
CADTH is pleased to announce the launch of its new Post-Market Drug Evaluation Program.
This important initiative fills a key gap in Canada’s drug safety and effectiveness landscape and is an exciting example of how CADTH is delivering on the “Innovate” pillar from its 2022-2025 Strategic Plan.…
September 1, 2022
CADTH recently experienced problems with its website hosting platform that prevented users from downloading documents from cadth.ca – including draft reimbursement recommendations and stakeholder feedback forms.
The issue has been resolved and all documents on our website are now accessible to…
August 30, 2022
CADTH is pleased to announce the introduction of the Real-World Evidence (RWE) Guidance Working Group which reports to the Real-World Evidence Steering Committee. The objective of this Guidance Working Group is to develop clear and comprehensive guidance on the conduct, reporting, and appraising of…
August 9, 2022
Held in April or May every year since 2005, the CADTH Symposium has traditionally been a spring event.
Because of the COVID-19 pandemic, the 2020 CADTH Symposium was delayed until late fall and we continued with a fall date in 2021.
Now we are preparing for a return to the CADTH Symposium’s…
July 13, 2022
CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.
The…
July 7, 2022
CADTH is pleased to announce the release of a new report entitled Building Toward a Potential Pan-Canadian Formulary: A Report From the Advisory Panel.
In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and managing a potential pan-Canadian…
June 30, 2022
CADTH is undertaking an innovative review for an antiviral treatment to address the recent monkeypox outbreaks.
Monkeypox has become a serious public health issue around the globe. According to WHO, the most recent case fatality ratio from monkeypox infection is about 3% to 6%. The causes of death…
June 27, 2022